WideCells Group’s (LON:WDC) subsidiary CellPlan has signed a non-binding letter of intent to offer its stem cell treatment insurance to clients of the human tissue storage facility Biovault Technical. Biovault has a register of over 25,000 customers which WideCells will have access to for an initial five year term.
WideCells CEO chief executive João Andrade tells Proactive: ”This is a very important landmark for us because we have developed the product and now the market’s responding positively to it. This letter of intent will allow us to have access directly to around 25,000 clients who Biovault currently has through their own company and also its affiliates and that will enable us to be able to rollout CellPlan during the course of next year”.
”What we’ll be doing, until the end of this year, is developing together with Biovault, an implementation plan and a market roll out plan because Biovault is operating in several countries – not just in the UK”, Andrade added.
Story by ProactiveInvestors